Table 2 Cross-sectional associations of 3 myocardial stress markers with kidney function assessed by eGFRcr-cysa.

From: Longitudinal and cross-sectional associations of myocardial stress markers with kidney function and chronic kidney disease in the BiomarCaRE project

Markers

Items

Categories of markersb

per 1 SD increase in log-transformed

G1

G2

G3

G4

NT-proBNP

Median, pg/ml

25.4

72.5

169.4

501.2

48.0

 

N

30,939

21,284

7109

2498

61,830

 

Model 1

Ref

−1.22 (−1.51, −0.94) ***

−4.23 (−4.66, −3.80) ***

−11.7 (−12.4, −11.0) ***

−2.32 (−2.47, −2.18) ***

 

Model 2

Ref

−1.41 (−1.69, −1.14) ***

−4.10 (−4.52, −3.68) ***

−11.2 (−11.8, −10.5) ***

−2.35 (−2.49, −2.21) ***

MR-proANP

Median, pmol/l

30.8

53.7

92.8

147.2

46.8

 

N

3540

4493

1048

418

9499

 

Model 1

Ref

−2.16 (−2.88, −1.45) ***

−5.30 (−6.43, −4.17) ***

−12.4 (−13.9, −10.8) ***

−2.83 (−3.20, −2.47) ***

 

Model 2

Ref

−2.68 (−3.39, −1.98) ***

−5.74 (−6.86, −4.62) ***

−11.8 (−13.4, −10.2) ***

−2.93 (−3.30, −2.57) ***

MR-proADM

Median, nmol/l

0.37

0.50

0.66

0.86

0.46

 

N

3492

4397

1029

409

9327

 

Model 1

Ref

−5.55 (−6.20, −4.89) ***

−12.4 (−13.5, −11.4) ***

−22.2 (−23.7, −20.7) ***

−5.84 (−6.17, −5.52) ***

 

Model 2

Ref

−5.24 (−5.90, −4.58) ***

−11.7 (−12.7, −10.6) ***

−21.0 (−22.6, −19.5) ***

−5.60 (−5.94, −5.26) ***

  1. aLinear regression was used to estimate beta coefficients and 95% CI of eGFR for G2-4 compared with G1 of markers, as well as for per 1 SD increase in log-transformed markers. Only results for eGFRcr-cys are presented in this table, while results for all three eGFR assessments are presented in Table S6.
  2. bCategories of NT-proBNP: G1: < 48; G2: 48–125; G3: 125–300; G4: ≥ 300 pg/ml. Categories of MR-proANP: G1: < 40; G2: 40–80; G3: 80–120; G4: ≥ 120 pmol/l. Categories of MR-proADM: G1: < 0.425; G2: 0.425–0.609; G3: 0.609–0.766; G4: ≥ 0.766 nmol/l.
  3. Model 1: adjusted for age, sex, and study cohort;.
  4. Model 2: model 1 plus body mass index, smoking status, alcohol consumption, systolic blood pressure, use of antihypertensive medication, high-density lipoprotein cholesterol, log-transformed triglycerides, diabetes, and cardiovascular diseases.
  5. CI, confidence interval; G, group; eGFR, estimated glomerular filtration rate; eGFRcr-cys, creatinine and cystatin C-based eGFR; MR-proADM, mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro-atrial natriuretic peptide; NT-proBNP, N-terminal pro-B-type natriuretic peptide; Ref, reference; SD, standard deviation.
  6. * p < 0.05, ** p < 0.01, *** p < 0.001.
Back to article page